MET expression and copy number status in clear-cell renal cell carcinoma: prognostic value and potential predictive marker.

ABSTRACT: Multiple targeted therapy for advanced clear-cell renal cell carcinoma (RCC) has substantially improved patient outcome, but complete remission is uncommon and many tumors eventually develop resistance. Mechanistic, preclinical, and early clinical data highlight c-Met / hepatocyte growth factor receptor as a promising target for RCC therapeutic agents.We have examined MET expression, frequency of MET gene copy gains and MET gene mutation in a large, hospital-based series of renal cell carcinomas with long-term follow-up information.Out of a total of 572 clear-cell RCC, only 17% were negative for MET expression whereas 32% showed high protein levels. High MET expression and MET copy number gains were associated with an aggressive phenotype and an unfavorable patient outcome. Elevated protei

SUBMITTER: Macher-Goeppinger S 

PROVIDER: S-EPMC5352033 | biostudies-literature | 2017 Jan

REPOSITORIES: biostudies-literature